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Human Werner Syndrome is characterized by early
onset of aging, elevated chromosomal instability, and a
high incidence of cancer. Werner protein (WRN) is a
member of the recQ gene family, but unlike other mem-
bers of the recQ family, it contains a unique 335 exo-
nuclease activity. We have reported previously that hu-
man Ku heterodimer interacts physically with WRN and
functionally stimulates WRN exonuclease activity. Be-
cause Ku and DNA-PKcs, the catalytic subunit of DNA-
dependent protein kinase (DNA-PK), form a complex at
DNA ends, we have now explored the possibility of func-
tional modulation of WRN exonuclease activity by DNA-
PK. We find that although DNA-PKcs alone does not
affect the WRN exonuclease activity, the additional
presence of Ku mediates a marked inhibition of it. The
inhibition of WRN exonuclease by DNA-PKcs requires
the kinase activity of DNA-PKcs. WRN is a target for
DNA-PKcs phosphorylation, and this phosphorylation
requires the presence of Ku. We also find that treatment
of recombinant WRN with a Ser/Thr phosphatase en-
hances WRN exonuclease and helicase activities and
that WRN catalytic activity can be inhibited by rephos-
phorylation of WRN with DNA-PK. Thus, the level of
phosphorylation of WRN appears to regulate its cata-
lytic activities. WRN forms a complex, both in vitro and
in vivo, with DNA-PKC. WRN is phosphorylated in vivo
after treatment of cells with DNA-damaging agents in a
pathway that requires DNA-PKcs. Thus, WRN protein is
a target for DNA-PK phosphorylation in vitro and in
vivo, and this phosphorylation may be a way of regulat-
ing its different catalytic activities, possibly in the re-
pair of DNA dsb.
Werner syndrome (WS)1 is a human autosomal recessive
disorder characterized by early onset of premature aging char-
acteristics including graying and loss of hair, wrinkling and
ulceration of skin, atherosclerosis, osteoporosis, and cataracts.
In addition, WS patients exhibit an increased incidence of
diabetes mellitus type 2, hypertension, and malignancies (1).
The gene (WRN), defects in which are responsible for WS,
encodes a 1,432-amino acid protein (WRN) (2) that has both
335 helicase and 335 exonuclease activities (3–7). Al-
though WRN appears to play an important role in DNA me-
tabolism, the precise cellular roles of both the helicase and
exonuclease activities of WRN remain to be determined.
Cells from patients with WS show premature replicative
senesence compared with cells derived from normal individuals
(8). The WS cellular phenotype suggests correlations among
faulty DNA metabolism, genomic instability, and senescence.
WS cells show hypersensitivity to selected DNA-damaging
agents including 4-nitroquinoline-1-oxide (4NQO) (9), topoi-
somerase inhibitors (10), and certain DNA cross-linking agents
(11). Compared with normal cells, WS cells also exhibit in-
creased genomic instability including higher levels of DNA
deletions, translocations, and chromosomal breaks (12, 13).
These studies suggest that WRN plays an important role in
DNA metabolism possibly by participating in DNA repair, rep-
lication, and/or recombination pathways.
We have previously identified a physical and functional in-
teraction between WRN and the Ku heterodimer (14). This
finding has been confirmed recently by an independent labora-
tory (15). Together with the catalytic subunit of the DNA-de-
pendent protein kinase (DNA-PKcs), Ku is required for repair
of DNA double strand breaks (dsb) generated during recombi-
nation and by reactive oxygen species resulting from endoge-
nous metabolism or treatment with ionizing radiation and cer-
tain mutagens (16). We have previously shown that Ku
significantly stimulates the 335 exonuclease activity of WRN
(14), suggesting that WRN and Ku could act in a common
pathway of DNA metabolism involving the exonuclease func-
tion of WRN. This hypothesis is supported by the observation
that mice lacking the Ku80 subunit show a premature aging
phenotype similar to that of WS patients (17). Furthermore,
cells deficient in WRN, Ku70, or Ku80 all show genomic insta-
bility and undergo premature replicative senescence (18, 19).
DNA dsb can be created by ionizing irradiation or during
V(D)J recombination, a process that generates immunological
diversity. One of the major pathways for the repair of dsb
involves an end-rejoining reaction that requires DNA-PK.
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DNA-PK is composed of a 465-kDa catalytic subunit (DNA-
PKcs) and the Ku70/80 heterodimer (20). The precise role of
DNA-PK in DNA dsb repair in mammalian cells is not clear,
but both Ku and DNA-PKcs are essential for the processing of
DNA ends. Current models predict that Ku binds to ends of
double-stranded DNA and then recruits DNA-PKcs to form the
active protein kinase complex. DNA-PK is essential for efficient
DNA dsb repair because cells lacking either DNA-PKcs or Ku
are sensitive to ionizing radiation and defective in V(D)J re-
combination (20). DNA-PK has been shown to phosphorylate a
variety of proteins in vitro, including SP1, SV40 T antigen, p53,
and replication protein A (20, 21). Although the kinase activity
of DNA-PK is required in vivo (22), its physiological substrates
are not known.
Because WRN has been shown to interact with Ku, we have
explored its role in the DNA-PK damage response pathway. In
this study we have examined functional interactions among
WRN, Ku, and DNA-PKcs. We find that DNA-PKcs, Ku, and
WRN interact on a DNA substrate and that DNA-PK down-
regulates the exonuclease activity of WRN. Correspondingly,
dephosphorylation of WRN increases its helicase and exonucle-
ase activities. We also show that WRN is phosphorylated in
vitro by DNA-PK and that DNA damage-induced phosphoryl-
ation of WRN is absent from a human cell that lacks DNA-




Amplified baculovirus was used to infect Sf9 insect cells for overex-
pression of WRN protein as described before (7). The protein was
purified by DEAE-Sepharose (Amersham Biosciences), Q-Sepharose
(Amersham Biosciences), and nickel-nitrilotriacetic acid (Invitrogen)
chromatography as described previously (7). Human Ku heterodimer
(23) and DNA-PKcs (24) were purified as reported. The purity of these
proteins was checked routinely, and they specifically did not contain
any ATM protein (data not shown). Baculovirus constructs for hexahis-
tidine-tagged full-length WRN protein were kindly provided by
Dr. Mathew Gray (University of Washington, Seattle).
Materials
Wortmannin and LY294002 were from Alexis Biochemicals. 4NQO
was from Janssen Chemical. Bleomycin sulfate was from Sigma. T4
polynucleotide kinase was from New England Biolabs. Protein phos-
phatase 1 (PP1) was from Roche Molecular Biochemicals. [-32P]ATP
was from PerkinElmer Life Sciences. ATP was purchased from Amer-
sham Biosciences.
DNA Substrates
Exonuclease Substrates—Single-stranded DNA oligomers (72-mer
and 53-mer) were obtained from Invitrogen. 7 pmol of 53-mer was
5-labeled with 60 Ci of [-32P]ATP (3,000 Ci/mmol) and 10 units of
polynucleotide kinase using standard conditions. To construct a double-
stranded DNA substrate with one blunt end and one 3-recessed (5-
overhang) end, labeled oligomer was mixed with a 2-fold excess of
unlabeled 72-mer, heated together at 90 °C for 5 min, then cooled slowly
to 25 °C. Annealed double-stranded substrates were then separated
from unannealed and excess single-stranded oligomers by nondenatur-
ing 12% PAGE. Intact double-stranded DNA substrates were recovered
using a Qiaex II gel extraction kit (Qiagen) and stored at 4 °C.
Helicase Substrates—PAGE-purified 44-mer and 19-mer oligonucleo-
tides were purchased from the Midland Certified Reagent Company.
The 19-bp duplex substrate with a 25-nucleotide 3-tail (3-overhang
DNA substrate) was constructed by labeling 10 pmol of 19-mer oligonu-
cleotide (5-GTAAAACGACGGCCAGTGC-3) at its 5-end using T4
polynucleotide kinase and [-32P]ATP. The labeled 19-mer was purified
from unincorporated nucleotide by using a Microspin G-25 column from
Amersham Biosciences. The 19-mer was mixed with 25 pmol of 44-mer
oligonucleotide (5-GCACTGGCCGTCGTTTTACGGTCGTGACTGGG-
AAAACCCTGGCG-3) in 50 mM NaCl, 10 mM Tris-Cl (pH 8.0), 1 mM
EDTA, heated at 100 °C for 5 min, then placed at 70 °C and allowed to
cool slowly (2 h) to 24 °C. The 19-bp duplex substrate with a 26-
nucleotide 5-fork and 25-nucleotide 3-tail (forked DNA substrate) was
prepared using the same protocol except 10 pmol of 45-mer oligonucleo-
tide (5-TTTTTTTTTTTTTTTTTTTTTTCCAAGTAAAACGACGGCCA-
GTGC-3) was annealed to 25 pmol of the 44-mer oligonucleotide de-
scribed above.
Exonuclease Assay
The assay to measure the 335 exonuclease activity of WRN was
carried out in 10 l at 37 °C with 40 mM Tris (pH 8.0), 5 mM MgCl2, 1
mM dithiothreitol, 0.1 mg/ml BSA, 10 mM ATP (25). 3 fmol of exonucle-
ase substrate was incubated with the indicated amount of Ku, DNA-
PKcs, and WRN. The reactions were initiated by the addition of WRN
and incubated at 37 °C for 60 min. Reactions were quenched by the
addition of an equal volume of formamide loading buffer (80% formam-
ide, 0.5 TBE, 0.1% bromphenol blue). The digestion products of these
reactions were separated on denaturing 14% polyacrylamide gels and
visualized using a PhosphorImager and quantitated using ImageQuant
software (Molecular Dynamics).
Band Shift Assay
For DNA binding activity the solution conditions were the same as
those used in the exonuclease assay. Approximately 3 fmol of 32P-
labeled exonuclease substrate was incubated on ice for 10 min with the
indicated amount of Ku, DNA-PKcs, and WRN in buffer containing 40
mM Tris (pH 7.8), 5 mM MgCl2, 1 mM dithiothreitol, 0.1 mg/ml BSA, and
10 mM ATP. 0.1% glutaraldehyde was added to the reaction, and incu-
bation continued for 5 min more. 10 l of DNA protein mixture was
analyzed by 4% nondenaturing gel electrophoresis at 4 °C at 250 V with
1 Tris acetate buffer for 1.5 h. DNA was visualized using a Phosphor-
Imager and analyzed using ImageQuant software.
In Vitro Phosphorylation
In vitro phosphorylation reactions were carried out either with the
same exonuclease buffer and substrate or with kinase buffer (50 mM
KCl, 1 mM dithiothreitol, 25 mM Hepes-KOH (pH 7.6), 5 mM MgCl2, 50
M ATP) with 100 ng of sonicated calf thymus DNA and 10 Ci of
FIG. 1. WRN exonuclease activity is inhibited by DNA-PKcs
only in the presence of Ku. A, 15 nM Werner protein was incubated
with 3 fmol of exonuclease substrate in kinase buffer with 15 nM Ku
and 0, 2.5, 5, 10, or 15 nM DNA-PKcs. The products were separated by
14% polyacrylamide gels under denaturing conditions and visualized
by phosphorimaging. B, quantitative scan of the lanes in A using
ImageQuant software (Molecular Dynamics). H.I., heat-inactivated
DNA-PKcs.
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[-32P]ATP. The reactions (10 l) were initiated by the addition of
DNA-PKcs and carried out at room temperature for 10 min. The reac-
tions were stopped with the addition of 1 l of 0.25 M EDTA. The
resulting products were analyzed by electrophoresis on 4–12% acryl-
amide Tris-glycine gel (Invitrogen). The gel was washed and visualized
as described above.
Phosphatase Reaction
2 nM WRN (final concentration) was incubated with the indicated
amounts of PP1 in a 15-l reaction (40 mM Hepes (pH 7.5), 7% glycerol,
50 mM KCl, 130 ng/l BSA, 11 mM MgCl2, and 3 mM ATP). The reaction
was incubated for 10 min at 24 °C.
DNA Helicase Assay
Immediately after the phosphatase reaction, 10 fmol of the DNA heli-
case substrate (5 l) was added to the reaction for a final volume of 20 l
(30 mM Hepes (pH 7.5), 5% glycerol, 40 mM KCl, 100 ng/l BSA, 8 mM
MgCl2, and 2 mM ATP). The mixture was then incubated for 15 min at
37 °C. The reaction was terminated by the addition of 10 l of 50 mM
EDTA, 40% glycerol, 0.9% SDS, 0.1% bromphenol blue, and 0.1% xylene
cyanol. The products of the helicase reaction were resolved by electro-
phoresis on 12% 1 TBE nondenaturing polyacrylamide gels. The radio-
labeled DNA products were visualized using a PhosphorImager as de-
scribed above. To determine the percentage of helicase substrate
unwound, the following formula was used: % displacement  100  P/(S
 P), where P is the product volume, and S is the substrate volume. The
values for P and S were corrected by subtracting background values in the
no-enzyme and heat-denatured controls, respectively.
ATPase Assay
123 fmol of WRN was incubated with 1 microunit of PP1 in a phos-
phatase reaction buffer (40 mM Hepes (pH 7.5), 7% glycerol, 50 mM KCl,
130 ng/l BSA, and 11 mM MgCl2). The reaction was incubated for 10
min at 24 °C. In control reactions, phosphatase was omitted. Immedi-
ately after the phosphatase reaction, 100 ng of M13mp18 single-
stranded DNA and 16 nmol of [3H]ATP were added to the reaction for
a final volume of 20 l (30 mM Hepes (pH 7.5), 5% glycerol, 40 mM KCl,
100 ng/l BSA, 8 mM MgCl2). The reaction was then incubated for 15
min at 37 °C and subsequently quenched with the addition of 10 l of
stop solution (100 mM EDTA, 20 mM ATP, 20 mM ADP). Products of the
ATPase reaction were resolved by thin layer chromatography and quan-
titated by scintillation counting.
Immunoprecipitation
For the in vitro reaction, purified WRN, Ku, and DNA-PKcs were
incubated with cold exonuclease substrate and buffer at 37 °C for 15
min. The reaction mixture was then incubated with either goat poly-
clonal anti-WRN (Santa Cruz Biotechnology) or polyclonal anti DNA-
PKcs (Santa Cruz Biotechnology) for 1 h at room temperature followed
by a 1-h incubation with G protein. After washing the complex with 50
mM Hepes (pH 7.4) and 0.5% Triton X-100, the immunoprecipitated
complex was separated in a 4–12% acrylamide Tris-glycine gel and
transferred to a polyvinylidene difluoride membrane. The membrane
was then incubated with mouse monoclonal anti-Ku70/Ku80 (Santa
Cruz Biotechnology, 1:500), mouse monoclonal anti-WRN (PharMingen,
1:250), and mouse monoclonal anti-DNA-PKcs (Oncogene, 1:1000) an-
tibody overnight at 4 °C followed by a 1-h incubation with horseradish
peroxidase-conjugated goat anti-mouse IgG (1:10,000). The resulting
signal was visualized with ECL plus a Western blotting detection sys-
tem (Amersham Biosciences). Immunoprecipitation with total cell ly-
sate was essentially the same as above; however, instead of purified
proteins, cell lysate was used. Cell lysate was precleared with G pro-
tein-agarose prior to immunoprecipitation.
In Vivo Phosphorylation
HeLa cells were grown for 24 h in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% fetal bovine serum. The human glioblas-
toma cell lines M059K (containing normal levels DNA-PKcs) and
M059J (lacking expression of DNA-PKcs) were grown in Dulbecco’s
modified Eagle’s medium and F-12 medium (Invitrogen) with 15% fetal
bovine serum. After 24 h, 2–5  106 cells were incubated with phos-
phate-free Dulbecco’s modified Eagle’s medium (Invitrogen) supple-
mented with 5% dialyzed fetal bovine serum for 1 h to exhaust the pool
of endogenous phosphate. The cells were then freshly supplemented
with phosphate-free medium containing 100 Ci of 32Pi (DuPont) for
5 h. In some experiments, DNA-damaging agents bleomycin (1 or 5
g/ml) or 4NQO (0.1 or 0.5 g/ml) were added during the incubation
period. In some experiments, cells were incubated with 25 M wortman-
nin. The radiolabeling was terminated by washing the cells with ice-
cold phosphate-buffered saline. The cells were then lysed with RIPA
buffer (150 mM NaCl, 1% Triton, 0.1% SDS, 10 mM Tris (pH 8), 0.5%
sodium deoxycholate, 0.2 mM phenylmethylsulfonyl fluoride, 20 g/ml
aprotinin, 10 g/ml leupeptine, 1 mM sodium orthovanadate, 10
units/ml DNase) supplemented with phosphatase inhibitors (1:1,000,
Sigma). After centrifugation at 12,000 rpm for 10 min at 4 °C, the
supernatant was precleared with G protein-agarose beads (Calbiochem)
and incubated with 4 g of polyclonal goat anti-WRN (from Santa Cruz
Biotechnology) for 4 h. The immune complexes were collected by adding
G protein-agarose beads and washed three times with RIPA buffer.
Immunoprecipitated proteins were analyzed on 8–16% acrylamide Tris-
glycine gels. The gels were washed and visualized by autoradiography.
RESULTS
DNA-PKcs Alone Does Not Affect WRN Exonuclease
We have shown previously that Ku can interact physically
with WRN and functionally stimulate WRN 335 exonuclease
activity (14). Because Ku and DNA-PKcs are subunits of DNA-
PK, which is involved in the repair of DNA dsb, we explored the
possibility that WRN exonuclease activity is modulated by
DNA-PKcs. The exonuclease activity of WRN was assayed us-
ing a duplex DNA substrate containing a 5-labeled, recessed
3-end and one blunt end. DNA-PKcs alone has no effect on
WRN exonuclease activity even at higher molar ratios (3.5:1) of
DNA-PKcs to WRN (data not shown).
FIG. 1—continued
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Inhibition of WRN Exonuclease Activity by DNA-PKcs in
the Presence of Ku
Because Ku functionally modulates the activities of both
WRN and DNA-PKcs, we assayed for the modulation of WRN
exonuclease activity by DNA-PK. In Fig. 1A, 15 nM Ku and 15
nM WRN were incubated in the presence of different amounts of
DNA-PKcs (2.5, 5, 10, and 15 nM) and exonuclease substrate in
kinase buffer. 15 nM Ku alone or 15 nM DNA-PKcs alone has no
effect on the substrate (lanes 2 and 3, respectively). WRN
exonuclease activity was not altered by equimolar amounts of
DNA-PKcs (lane 5). In lane 6, it was observed that Ku stimu-
lated WRN exonuclease activity, as the degradation products
were smaller in molecular size. We have reported this stimu-
lation previously (14). To address the possibility that Ku het-
erodimer stimulates WRN exonuclease activity by enhancing
the processivity of WRN exonuclease, we conducted unlabeled
DNA competitor experiments. Unlabeled DNA substrate added
in increasing amounts to ongoing WRN exonuclease reactions
effectively quenched the WRN exonuclease reactions in the
absence of Ku; however, the presence of Ku rendered the WRN
exonuclease reaction resistant to quenching by a 10-fold molar
excess of unlabeled DNA substrate (data not shown). These
results suggest that the effect of Ku on WRN exonuclease is to
render the enzyme more processive.
When DNA-PKcs was added to the reactions containing
WRN and Ku, WRN exonuclease activity was inhibited mark-
edly (Fig. 1A, lanes 7–10). At the highest concentration of
DNA-PKcs used (corresponding to equimolar amounts of DNA-
PKcs, Ku, and WRN) the WRN exonuclease activity was inhib-
ited strongly (Fig. 1, lane 10). Similar results were also ob-
served when kinase buffer was replaced by exonuclease buffer
(data not shown). In Fig. 1B, we have scanned the lanes from
the gel in Fig. 1A. It is evident from the patterns of digestion
products shown by the scan analysis that DNA-PK inhibited
WRN exonuclease activity. We also calculated the exonuclease
activity based on the amount of undigested (full-length) sub-
strate. It was 0.184  0.12% fmol in the presence of 15 nM
WRN. When 15 nM Ku was present this became 0.1  0.5%, and
in the additional presence of 5, 10, and 15 nM DNA-PKcs, it
became 0.55  0.14, 0.8  0.15, and 1.38  0.28%, respectively.
The fraction of digested product (20-mer) for the reaction
containing WRN alone or WRN  DNA-PKcs was 42  4 and
44  6%, respectively. In the presence of Ku and WRN this
fraction became 64  6%. The addition of 5, 10, and 15 nM
DNA-PKcs to the exonuclease reactions containing WRN and
Ku yielded values of 57  7, 48  5, and 36  6%, respectively,
for products 20-mer. These data, representing an average of
three experiments, clearly demonstrate that DNA-PKcs and
Ku together effectively inhibit the WRN exonuclease reaction.
The addition of DNA-PKcs inhibits the ability of Ku alone to
stimulate WRN exonuclease activity, instead reducing exonu-
clease activity to levels less than observed with WRN alone.
Incubation with Kinase Inhibitors Can Restore WRN
Exonuclease Activity
DNA-bound Ku is required for maximal stimulation of the
protein kinase activity of DNA-PKcs (26), and the protein ki-
nase activity of DNA-PK is inhibited by 50–100 nM wortman-
nin or 50–100 M LY294002 (27). The presence of wortmannin
or LY294002 in the Ku/DNA-PKcs/WRN incubation reaction
prevented the DNA-PK-dependent inhibition of WRN exonu-
clease activity (Fig. 2A, lanes 6 and 7). DNA-PKcs was prein-
cubated with 100 nM wortmannin and 100 M LY294002 to
inhibit the DNA-PKcs kinase activity completely. In lane 3, it is
shown again that DNA-PKcs itself did not affect the WRN
exonuclease activity, whereas the inhibition of the exonuclease
in the presence of Ku and DNA-PKcs was observed (lane 5).
Neither wortmannin nor LY294002 had any effect on WRN
exonuclease activity or the Ku stimulation of the WRN exonu-
clease activity (data not shown). Thus, it appears that the
protein kinase activity of DNA-PK is essential for the inacti-
vation of WRN exonuclease activity.
C-terminal Ku80 Is Required for DNA-PK Inhibition of
WRN Exonuclease Activity
To confirm that the protein kinase activity of DNA-PKcs was
essential for inhibition of WRN exonuclease activity, we tested
a form of DNA-PK which is defective in protein kinase activity.
The C-terminal 12 amino acids of Ku80 have been shown to be
essential for the interaction of DNA-PKcs with Ku (28). A
mutant form of the Ku heterodimer with full-length Ku70 but
missing the C-terminal 162 amino acids of Ku80 (Ku70/80C)
is fully able to bind DNA but does not support DNA-PK protein
kinase activity.2 When this mutant form of Ku was incubated
with WRN and DNA-PKcs, there was no inhibition of WRN
exonuclease activity (Fig. 2B). These data support the hypoth-
esis that the active DNA-PK (DNA-PKcs  Ku) is required for
abrogation of the exonuclease activity of WRN.
WRN Is Phosphorylated by DNA-PKcs Only in the
Presence of Ku
We next tested whether WRN is a substrate of DNA-PK.
Different combinations of WRN, Ku, and DNA-PKcs were in-
cubated with sonicated calf thymus DNA as an effector and
with [-32P]ATP (Fig 3). Fig. 3 shows that WRN is phosphoryl-
ated only in the presence of both Ku and DNA-PKcs but not by
either Ku or DNA-PKcs alone (lanes 1 and 2). The presence of
wortmannin inhibited the phosphorylation of the four proteins
(lane 5). DNA-PK phosphorylated Ku and autophosphorylated
itself only when Ku was present (lane 3). Thus, we show that
WRN can be phosphorylated by DNA-PK in vitro and that Ku
is required for this phosphorylation. Phosphorylation of DNA-
PKcs, Ku70, and Ku80 (Fig. 3, lane 3) represents autophospho-
rylation of DNA-PK (29). The WRN phosphorylation by
DNA-PK was also confirmed under the reaction conditions for
the exonuclease activity assay (data not shown), providing fur-
ther evidence for the correlation between WRN phosphoryla-
tion and inhibition of its exonuclease activity.
Ku Mediates the Interaction between WRN and DNA-PKcs
To explore further the potential interactions among WRN,
Ku, and DNA-PKcs, we conducted electrophoresis mobility
shift assays, using the same buffers and substrate conditions as
in the WRN exonuclease assay (Fig. 4). 5 nM Ku and 5 nM WRN
were incubated with 1, 2.5, and 5 nM DNA-PKcs in the presence
of exonuclease DNA substrate on ice for 10 min, and the re-
sulting products were separated on 4% native polyacrylamide
gels. Many studies have shown that Ku interacts with DNA
substrates to form proteinDNA complexes in electrophoresis
mobility shift assays. However, DNA-PKcs does not interact
with DNA in this assay, and the interaction among DNA-PKcs,
Ku, and DNA is weak in the absence of cross-linkers (30). Here,
we used 0.1% glutaraldehyde to stabilize the complex. As ex-
pected, WRN or DNA-PKcs, separately or together, did not
alter the mobility of the DNA probe (Fig. 4, lanes 2, 3, and 5,
respectively), whereas the KuDNA substrate complex dis-
played a gel mobility shift (lane 4). When Ku was present with
either DNA-PKcs or WRN, a supershift was observed (lanes 6
and 7, respectively). When all three proteins were present, a
further mobility shift was observed. With increasing amounts
2 C. M. Snowden and D. A. Ramsden, unpublished observations.
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of DNA-PKcs, the intensity of the supershifted bands was in-
creased (lanes 8, 9, and 10). Interaction of the 156-kDa Ku
heterodimer, 465-kDa DNA-PKcs, plus 167-kDa WRN formed a
large proteinDNA complex that migrated a short distance into
the gel. When treated with 1% SDS, the proteins dissociated,
and the substrate was released (lane 11). The results suggest
mutual bindings among WRN, Ku, and DNA-PKcs, and the
possible interaction between DNA-PKcs and WRN would be
mediated through Ku.
Physical Association between WRN and DNA-PKcs in Vivo
and in Vitro
In vitro association of WRN with DNA-PK was investigated
by mixing 5 nM purified WRN, Ku, and DNA-PKcs (final con-
centration of each) in vitro in the presence of exonuclease buffer
and substrate, followed by immunoprecipitation with an anti-
body against WRN. The presence of WRN, Ku, and DNA-PKcs
in the immunoprecipitated complex was determined by conven-
tional Western blotting using the respective antibodies. As
shown in Fig. 5A, WRN was physically associated with Ku (lane
1). Under our reaction conditions DNA-PKcs was not physically
associated with WRN (lane 2). However, WRN was physically
associated with DNA-PKcs in the presence of Ku (lane 4).
Moreover, in the presence of DNase, the physical association
between WRN and DNA-PK was still present and unchanged
(lane 5). Also, goat IgG did not immunoprecipitate any proteins
from the purified mixture (lane 8). This experiment suggests that
the interaction between WRN and DNA-PKcs is mediated by Ku.
To address whether this in vitro physical association also
occurs in vivo, we immunoprecipitated this complex from a
HeLa cell lysate. As seen in Fig. 5B, any of the three proteins
can be immunoprecipitated by any of the three antibodies
against WRN, Ku, or DNA-PKcs, indicating that they form a
complex in vivo. As a control, we used WRN mutant skin
fibroblasts cells, AG11395, where WRN antibody could not
precipitate any protein (lane 7). However, in these mutant
cells, Ku immunoprecipitated DNA-PKcs, and thus, as ex-
pected, the association between Ku and DNA-PKcs takes place
in the absence of WRN (lane 8). Input was 10% of the lysate
used in each immunoprecipitation experiment. As a control we
used goat IgG, which does not immunoprecipitate either of the
proteins mentioned above from HeLa cell lysate (Fig. 5B, lane 2).
WRN Is Phosphorylated when Expressed in Insect Cells
Because DNA-PK phosphorylates substrates at Ser/Thr res-
idues, we first determined whether recombinant WRN has such
phosphorylation sites. Purified WRN recombinant protein was
treated with PP1, which specifically removes phosphate from
serine or threonine residues. As seen in Fig. 6A, the bands
corresponding to WRN as detected by antibody to Ser/Thr phos-
phate disappeared with increasing amounts of PP1. Thus, re-
combinant WRN protein, when expressed in insect cells, con-
tained phosphorylated residues at Ser/Thr.
Because it was possible that dephosphorylation of WRN
could remove phosphate groups that were essential for recog-
nition of WRN by DNA-PK, we first treated WRN (directly
purified from insect cells) with PP1, then inhibited the protein
phosphatase by adding sodium orthovanadate, and then deter-
mined whether DNA-PK could rephosphorylate the dephospho-
rylated WRN. As shown in Fig. 6B, pretreatment with PP1
(lane 2) did not affect the ability of DNA-PK to phosphorylate
WRN at Ser/Thr residues (compare lanes 3 and 4). The anti-
body against Ser/Thr phosphate also detects bands correspond-
ing to the phosphorylation of Ku and DNA-PKcs. The presence
of an equal amount of WRN or Ku was verified (Fig. 6, C and
D). We also show that PP1 can remove the phosphate, which is
incorporated by DNA-PK by treating the WRNDNA-PK com-
plex with PP1 after the kinase reaction was stopped with
wortmannin. As seen in Fig. 6E, the intensity of the incorpo-
FIG. 2. A, the phosphatidylinositol 3-kinase inhibitors wortmannin
and LY294002 restore WRN exonuclease activity. Where indicated, 15
nM DNA-PKcs was preincubated for 10 min at room temperature with
either 100 nM wortmannin or 100 M LY294002 before addition to the
reaction mixtures. Reaction mixtures contained 15 nM WRN protein, 15
nM Ku, 3 fmol of exonuclease substrate, and exonuclease buffer. The
reactions were incubated for 1 h at 37 °C. The products were separated
by 14% denaturing PAGE and visualized by phosphorimaging. B, Ku
interaction with DNA-PKcs is necessary for inhibition of WRN exonu-
clease activity. 15 nM recombinant Ku70/Ku80C in which the C-ter-
minal 162 amino acids of Ku80 were deleted was incubated with 15 nM
WRN and 5, 10, or 15 nM DNA-PKcs with exonuclease substrate (lanes
2-4, respectively). The products were separated on 14% polyacrylamide
gels under denaturing electrophoresis, and the gels were visualized by
phosphorimaging
FIG. 3. WRN phosphorylation requires Ku. Ku, DNA-PKcs, and
WRN (each at 15 nM) were incubated in combination with a kinase
buffer, sonicated calf thymus DNA, and [-32P]ATP for 10 min at room
temperature. The products were separated on 4–12% Tris-glycine ac-
rylamide gels and visualized by phosphorimaging. Lane 1, WRN 
DNA-PKcs. Lane 2, Ku  WRN. Lane 3, Ku  DNA-PKcs. Lane 4, WRN
 Ku  DNA-PKcs. Lane 5, WRN  Ku  DNA-PKcs  100 nM
wortmannin.
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rated radioactive phosphate decreased after the PP1 treat-
ment. This experiment clearly demonstrated that PP1 specifi-
cally removes phosphate, which was incorporated by DNA-PK,
from WRN.
Given that DNA-PK phosphorylates WRN protein, we were
next interested in whether this phosphorylation might affect
any of the WRN catalytic activities. WRN has three character-
ized catalytic activities: an exonuclease function, a helicase
function, and a DNA-dependent ATPase activity.
Dephosphorylation Enhances WRN Exonuclease Activity
We have shown that WRN is phosphorylated by DNA-PK in
vitro and that the exonuclease activity of WRN is inhibited
under conditions in which DNA-PK is active. PP1 has been
shown to remove serine and threonine phosphate incorporated
into DNA-PKcs and Ku by autophosphorylation (31). Protein
phosphatase regulates DNA-PK activity. PP1 was shown to
remove endogenous phosphate from baculovirus-expressed
WRN (Fig. 6A) and from WRN that had been phosphorylated
by DNA-PK in vitro (Fig. 6E). These data therefore suggested
that PP1 could be used as a tool to characterize the effect of
phosphorylation on the activities of WRN.
We next examined whether PP1 was able to modulate the
exonuclease activity of WRN. As shown in Fig. 7A, it was
observed that treatment of purified, recombinant WRN with
increasing amounts of PP1 enhanced the WRN exonuclease
activity significantly (lanes 3–6). In the presence of WRN the
percent of digested product 20-mer was 33  5. When WRN
was preincubated with PP1 the percent of digested product
20-mer increased with the amount of PP1 used (0.1 unit, 36 
7%; 0.25 unit, 39  7%; 0.5 unit, 45  4%; 1 unit, 56  7%).
Heat-inactivated PP1 did not affect WRN exonuclease (lane 8).
Thus, dephosphorylation of baculovirus expressed WRN en-
hanced its exonuclease activity.
The stimulating effect of PP1 treatment on WRN exonucle-
ase activity may be caused by the enhancement of enzyme
processivity. To address this possibility, we tested the effect of
adding unlabeled DNA substrate to an ongoing WRN exonu-
clease reaction. The exonuclease reaction was initiated by the
addition of WRN that was either untreated or treated with 10
nM PP1 to 3 fmol of radiolabeled DNA substrate. After 2 min of
incubation at 37 °C, specific amounts of unlabeled DNA sub-
strate (3, 6, and 15 fmol) were added to the reaction, and the
reactions were allowed to incubate for an additional 8 min. The
products were resolved on denaturing polyacrylamide gels. As
seen in Fig. 7B, the exonuclease activities of both WRN or
PP1-treated WRN were inhibited by the presence of increasing
amounts of unlabeled DNA substrate in a dose-dependent man-
ner. Quantification of the scanned lanes yielded the percent of
undigested substrate 43-mer for WRN with increasing
amounts of unlabeled substrate DNA; at 0, 3, 6, and 15 fmol,
the percents were 80  3, 84  1.8, 93  2.6, and 95  5,
respectively, whereas the corresponding values for PP1-treated
WRN were 53  9, 63  2.4, 71  8, and 86  1.8%. These
FIG. 4. Ku mediates interaction between WRN and DNA-PKcs.
The DNA binding ability of 5 nM Ku, 5 nM WRN, and 1, 2.5, or 5 nM
DNA-PKcs either alone or in combination was monitored by band shift
assay. Lane 1, no enzyme. Lane 2, 5 nM WRN. Lane 3, 5 nM DNA-PKcs.
Lane 4, 5 nM Ku. Lane 5, 5 nM WRN  5 nM DNA-PKcs. Lane 6, 5 nM
WRN  5 nM Ku. Lane 7, 5 nM Ku  5 nM DNA-PKcs. Lanes 8–10, 5 nM
Ku  5 nM WRN  1, 2.5, and 5 nM DNA-PKcs. Lane 11, same as lane
10, but with 1% SDS.
FIG. 5. A, in vitro immunoprecipitation. 5 nM Ku, 5 nM WRN, and 5
nM DNA-PKcs were incubated in different combination with exonucle-
ase substrate (unlabeled) and buffer. The protein mixture was immu-
noprecipitated with antibody against WRN or DNA-PKcs. Lane 1, WRN
 Ku (immunoprecipitated with WRN antibody). Lane 2, WRN  DNA-
PKcs (immunoprecipitated with WRN antibody). Lane 3, Ku  DNA-
PKcs (immunoprecipitated with DNA-PKcs antibody. Lane 4, WRN 
Ku  DNA-PKcs (immunoprecipitated with WRN antibody). Lane 5,
WRN  Ku  DNA-PKcs  DNase (immunoprecipitated with WRN
antibody). Lane 6, purified proteins. Lane 7, purified proteins. Lane 8,
WRN  Ku  DNA-PKcs (immunoprecipitated with goat IgG). B, im-
munoprecipitation from cell lysate. HeLa cell lysate was immunopre-
cipitated with the antibody against WRN, Ku, or DNA-PKcs. Lane 1,
HeLa cell lysate as input. Lane 2, HeLa cell lysate immunoprecipitated
with goat IgG. Lane 3, HeLa cell lysate immunoprecipitated with WRN
antibody. Lane 4, HeLa cell lysate immunoprecipitated with Ku anti-
body. Lane 5, HeLa cell lysate immunoprecipitated with DNA-PKcs
antibody, Lane 6, WRN mutant AG11395 cell lysate as input. Lane 7,
AG11395 cell lysate immunoprecipitated with WRN antibody. Lane 8,
AG11395 cell lysate immunoprecipitated with Ku antibody. Input (ei-
ther HeLa or AG11395, lane 1 and lane 6, respectively) is 10% of the
lysate used in each immunoprecipitation experiment. IB, immunoblot.
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results suggest that the processivities of WRN and PP1-treated
WRN are similar. A similar effect of unlabeled DNA competitor
on WRN exonuclease activity was observed when a higher
concentration of WRN (30 nM) was used (data not shown). Thus,
PP1 treatment of WRN did not enhance its processivity. Within
the range of WRN phosphorylation status that we have been
studying (before and after PP1 treatment), we found no change in
DNA binding as observed by band shift assay (data not shown).
We have shown that DNA-PK could rephosphorylate WRN
that had been PP1-treated, and we then asked whether rephos-
phorylation of WRN would affect the exonuclease function. As
seen in Fig. 7C the exonuclease activity of WRN was increased
after dephosphorylation (compare lanes 2 and 3). After rephos-
phorylation with DNA-PK (lane 4) the WRN exonuclease activ-
ity was strongly inhibited. In lane 5, we show that the Ku
heterodimer stimulated the exonuclease activity of the dephos-
phorylated WRN. Thus, the presence of DNA-PKcs in the
WRN-Ku reaction was responsible for the inhibition of WRN
exonuclease activity. This experiment along with the experi-
ment shown in Fig. 6B demonstrate that phosphorylation by
DNA-PKcs can regulate WRN exonuclease activity.
Dephosphorylaton of WRN Enhances Its Helicase Activity
on Duplex DNA Substrates
3-Tailed Substrate—We next examined whether WRN Ser/
Thr phosphorylation status affected its helicase activity. 1.5 nM
WRN (final concentration) was incubated with 1 microunit of
PP1 or PP1 storage buffer and analyzed for helicase activity. As
shown on the gel (Fig. 8A, lane 3) WRN that was not treated
with PP1 unwound 35% of the 3-overhang helicase substrate.
When WRN was pretreated with PP1 the unwinding increased
to 58% (lane 4). This represents a 1.7-fold increase in WRN
helicase activity on the 3-overhang substrate for phosphatase-
treated WRN compared with the untreated WRN protein. Im-
portantly, PP1 did not destabilize the DNA substrate (Fig. 8A,
lane 2), and heat-denatured PP1 was unable to enhance WRN
helicase activity (data not shown). Also, 1 microunit of PP1 was
unable to enhance the helicase activity of a WRN ATPase
mutant protein (WRN K577M) that lacks helicase activity (32
and data not shown). Quantification of WRN helicase activity
on the 3-tailed duplex as a function of PP1 treatment is shown
in Fig. 8C.
Forked Substrate—WRN was preincubated with PP1 or PP1
storage buffer and analyzed for helicase activity on a forked
duplex substrate. In the absence of PP1, WRN catalyzed 8 and
12% unwinding of the forked duplex substrate at WRN concen-
trations of 100 and 380 pmol/liter, respectively (Fig. 8B, lane 2
in each gel). 1 microunit of PP1 enhanced WRN helicase activ-
ity 3.5-fold (28% substrate unwound) and 4.8-fold (57% sub-
strate unwound) at WRN protein concentrations of 100 and 380
pmol/liter, respectively (Fig. 8B, lane 3 in each gel). A quanti-
tative representation of the data is shown in Fig. 8D.
The DNA-dependent ATPase activity of WRN was also tested
after PP1 treatment. Although the other catalytic activities of
WRN are enhanced significantly after PP1 treatment, there is
no marked change in its ATPase activity (data not shown).
Thus, the enhanced helicase activity of dephosphorylated WRN
is not the result of a major change in its ATP-hydrolyzing
activity.
Presence of Kinase Inhibitor or PP1 Treatment Does Not
Dissociate the WRNKuDNA-PKcs Complex
We next determined whether the presence of kinase inhibitor
or PP1 treatment could affect the complex formation among
WRN, Ku, and DNA-PKcs using electrophoresis mobility shift
assays. The results are shown in Fig. 9A. Lane 2 represents the
WRNKuDNA-PKcs complex alone. With increasing concentra-
tions of wortmannin (50, 100, 150 nM) the band pattern did not
change (lanes 3–5). Also, the presence of 0.25, 0.5, and 1 unit of
PP1 in the reaction mixture did not change the complex forma-
tion (lanes 6–8). Treatment with 1% SDS dissociates the com-
FIG. 6. A, WRN phosphorylation in insect cells. WRN protein is
partially phosphorylated when expressed in insect cells. 10 nM purified
WRN protein was treated with different amounts of PP1 (0.1, 0.5, and
1 unit) in phosphatase buffer for 10 min at room temperature and then
separated on 4–12% acrylamide Tris-glycine gels. Conventional West-
ern blotting was performed using antibody against Ser/Thr phosphate.
The upper panel shows the bands as detected by antibody against
Ser/Thr phosphate disappear gradually with increasing amounts of
PP1. The same membrane was stripped and reprobed with WRN anti-
body to confirm that an equal amount of protein was present in the PP1
treatment, as seen in the lower panel. B, rephosphorylation of dephos-
phorylated WRN. 20 nM recombinant WRN was either mock-treated or
treated with 0.5 unit of PP1 for 10 min at room temperature. The
activity of PP1 was inhibited by adding 1 mM of sodium orthovanadate
and followed by phosphorylation with DNA-PK. The reaction products
were analyzed by conventional Western blotting using a Ser/Thr phos-
phate antibody. Lane 1, recombinant WRN mock-treated with PP1.
Lane 2, recombinant WRN treated with PP1. Lane 3, PP1 mock-treated
WRN followed by phosphorylation. Lane 4, PP1-treated WRN followed
by phosphorylation. DNA-PK phosphorylates both PP1-treated and
mock-treated WRN (lanes 3 and 4). The same membrane was stripped
and reprobed with WRN antibody (C) and Ku 70/80 antibody (D). The
mixture of 10 nM WRN, 10 nM Ku, and 10 nM DNA-PKcs was incubated
with 10 Ci of [32P-]ATP for 10 min at room temperature. The reaction
was stopped by adding 100 nM wortmannin and followed by 0.25 unit
and 0.5 unit of PP1 (E). The final reaction products were separated on
a 4–12% Tris-glycine acrylamide gel, and bands were visualized by
phosphorimaging. IB, immunoblot.
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plex from the substrate (lane 9). We also found that the
WRNKuDNA-PKcs complex formed in vitro was unaffected by
PP1 treatment (Fig. 9B). These results suggest that the phys-
ical association among WRN, Ku, and DNA-PKcs does not
change in the presence of kinase inhibitor or after PP1
treatment.
WRN Is Phosphorylated in Vivo after DNA Damage
DNA-PK is required for the repair of DNA dsb induced by
ionizing radiation, bleomycin, or other agents (20). Because WS
cells are hypersensitive to 4NQO (9), an agent that produces
oxidative DNA damage by the formation of radicals, which can
ultimately cause DNA dsb, it is likely that WRN participates in
this DNA damage response pathway. Indeed, the presence of
both helicase and exonuclease activities within the WRN pro-
tein makes it an ideal candidate for processing of damage-
induced DNA ends. We therefore tested whether WRN is phos-
phorylated in vivo in response to induced DNA damage.
HeLa cells were treated with bleomycin or 4NQO. As shown
in Fig. 10, treatment with bleomycin induced phosphorylation
of WRN in a dose-dependent manner (Fig. 10A). Treatment of
the cells in culture with 4NQO also induced WRN phosphoryl-
ation (Fig. 10B). The upper panels in Fig. 10, A and B, show the
silver staining of the gel, demonstrating that equal amounts of
proteins were loaded. When the HeLa cells were preincubated
with 25 M wortmannin for 1 h before the addition of bleomy-
cin, the amount of incorporated phosphate decreased signifi-
cantly, suggesting that the activity of kinases belonging to the
phosphatidylinositol 3-kinase family were responsible for phos-
phorylation of WRN in vivo (Fig. 10C). To demonstrate that
DNA-PKcs is a major kinase that phosphorylates WRN, we
used human cell lines with (M059K) or without (M059J) DNA-
PKcs (33). M059J are highly radiosensitive and fail to express
DNA-PKcs because of a message instability (34). Bleomycin
treatment of the cells induced phosphorylation of WRN only in
M059K cells (Fig. 10D) and not in the DNA-PKcs-deficient cell
line, M059J. Silver staining of the protein showed similar load-
ing in the respective lanes. Thus, WRN phosphorylation occurs
in vivo after DNA damage and is deficient in a cell line with
loss of DNA-PKcs function.
DISCUSSION
We show that WRN is phosphorylated by DNA-PK in vitro
and that DNA damage-induced phosphorylation of WRN is
absent in a human cell line that lacks DNA-PKcs. We also show
that the phosphorylation of WRN inhibits its exonuclease ac-
tivity, whereas dephosphorylation of WRN enhances both its
exonuclease and helicase activities. Thus, the Ser/Thr phospho-
rylation status of WRN plays a role in the regulation of its
catalytic activities. Furthermore, a complex is formed between
DNA-PK and WRN in vivo and in vitro, and this complex
formation does not appear to be dependent upon phosphoryla-
tion status of these proteins. Thus, WRN protein is a target of
DNA-PK phosphorylation, and the catalytic activities of WRN
are regulated by phosphorylation. These observations suggest
that WRN participates in a DNA-PK pathway of DNA metab-
FIG. 7. A, dephosphorylation of WRN increases its exonuclease activity. 10 nM WRN protein was preincubated with PP1 or with PP1 storage
buffer before using for exonuclease assay. The reaction conditions and substrate were the same as those in the exonuclease assay. The products
were separated by 14% denaturing polyacrylamide gels and visualized by phosphorimaging. Lane 1, no enzyme control. Lane 2, exonuclease
substrate with 1 unit of PP1. Lanes 3–7, WRN treated with 0, 0.1, 0.25, 0.5, and 1 unit of PP1, respectively, before the exonuclease reaction. Lane
8, effect of 1 unit of heat-inactivated PP1 on WRN exonuclease activity. B, dephosphorylation does not change the processivity of WRN. The
exonuclease activity of PP1-treated or untreated WRN was assayed with increasing amounts of unlabeled DNA substrate. Lane 1, no enzyme. Lane
2, 10 nM WRN. Lane 3, WRN  3 fmol of unlabeled DNA substrate. Lane 4, WRN  6 fmol of unlabeled DNA substrate. Lane 5, WRN  15 fmol
of DNA substrate. Lane 6, 10 nM WRN treated with 0.5 unit of PP1. Lane 7, PP1-treated WRN  3 fmol of unlabeled DNA substrate. Lane 8,
PP1-treated WRN  6 fmol of unlabeled DNA substrate. Lane 9, PP1-treated WRN  15 fmol of unlabeled DNA substrate. C, phosphorylation of
dephosphorylated WRN further inhibits WRN exonuclease activity. 10 nM WRN was incubated with either PP1 storage buffer or 0.5 unit of PP1
for 10 min at room temperature. PP1 was inactivated with the addition of 1 mM sodium orthovanadate. Later, the exonuclease substrate was added
to the reaction with or without 10 nM Ku and 10 nM DNA-PKcs. Lane 1, no enzyme control. Lane 2, exonuclease activity of recombinant WRN. Lane
3, exonuclease activity of dephosphorylated WRN. Lane 4, presence of DNA-PK (Ku  DNA-PKcs) with dephosphorylated WRN. Lane 5, presence
of Ku with dephosphorylated WRN. The reaction products were separated on a 14% denaturing polyacrylamide gel and visualized by
phosphorimaging.
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olism. We find that the presence of kinase inhibitors or PP1
does not change the physical association between WRN and
DNA-PK, and we conclude that physical association between
DNA-PK and WRN is not critical for this inhibition of WRN
exonuclease activity. Incubation with kinase inhibitors re-
stores WRN exonuclease from DNA-PK-mediated inhibition.
DNA-PK is required for the repair of DNA dsb via the non-
homologous end joining (NHEJ) pathway, and cells that lack
DNA-PK are defective in DNA dsb repair. Although the precise
mechanism of NHEJ has not been elucidated it is proposed that
Ku binds to a DNA dsb and that DNA-PKcs is subsequently
recruited to form an active protein kinase complex. Other pro-
teins such as XRCC4 and DNA ligase IV are then recruited to
ligate the DNA ends together. Although the physiological sub-
strates of DNA-PK are not known, the protein kinase activity of
human DNA-PKcs is required in DNA dsb rejoining (22), and
ATP is required for NHEJ in vitro (35). Studies in cell-free
extracts suggest that proteins in addition to DNA-PKcs, Ku,
XRCC4 and DNA ligase IV are required for NHEJ. It is likely
that such additional proteins may play a role in processing
DNA ends prior to ligation. Based on current models this proc-
essing is thought to involve both helicase and 335 exonucle-
ase activity. The Mre11 component of the Mre11Rad50Nbs1
complex has 335 exonuclease activity and may function in
NHEJ. It has been suggested that Ku might function as a
helicase in NHEJ (26) based on previous observations that Ku
can have helicase activity (36). However, in this laboratory, we
have tested Ku activity on a variety of helicase substrates, and
we have not found unwinding ability of the heterodimer on any
substrate.3 Because WRN has both helicase and 335 exonu-
clease activity and interacts with Ku and DNA-PK, WRN could
potentially accomplish both of the putative processing steps of
NHEJ. If WRN is essential in NHEJ, WS(	/	) cells would be
expected to be more sensitive than normal cells to treatment
3 P. Karmakar, J. Piotrowski, R. M. Brosh, Jr., J. A. Sommers, S. P.
Lees Miller, W.-H. Cheng, C. M. Snowden, D. A. Ramsden, and V. A.
Bohr, unpublished results.
FIG. 8. A, dephosphorylation of WRN with PP1 enhances its helicase activity. 1.5 nM WRN (final concentration) was preincubated with 0 (lane
3) or 1 microunit (lane 4) of PP1 followed by incubation with a 3-tailed duplex DNA substrate as described under “Experimental Procedures.” Lane
1, substrate alone control. Lane 2, DNA substrate incubated with 1 microunit of PP1 but no WRN. Lane 5, heat-denatured DNA substrate control.
Products were resolved by electrophoresis on a 12% nondenaturing polyacrylamide gel. B, WRN helicase activity on a forked DNA duplex is
stimulated by dephosphorylation. 100 or 380 pmol/liter WRN protein (as indicated) was preincubated with PP1 storage buffer (lane 2) or 1
microunit of PP1 (lane 3) followed by incubation with a forked duplex DNA substrate as described under “Experimental Procedures.” Lane 1,
substrate alone control. Lane 4, heat-denatured helicase substrate control. Products were resolved by electrophoresis on a 12% nondenaturing
polyacrylamide gel. C and D, quantitation of WRN helicase activity. U, microunit. C, the percent substrate unwound by WRN as a function of PP1
is shown for the 3-tail substrate. D, the percent substrate displaced by 100 or 380 pmol/liter WRN (as indicated) as a function of PP1 is shown for
the forked duplex substrate. Data points represent the mean values of at least three independent experiments with standard deviations indicated
by error bars.
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with agents that introduce lesions that are removed via the
NHEJ pathway. Some studies have shown a hypersensitivity of
WS cells to -irradiation, but others have not (37). Recently,
using a fluorescence in situ hybridization technique, it was
demonstrated that x-rays could induce more DNA fragmentation
in WS cells than in normal cells (38). WS cells are also hypersen-
sitive to DNA cross-linking agents which ultimately can give rise
to dsb (11). These studies suggest that WRN may have a role in
repair of DNA damage which is repaired by NHEJ.
Recently Yannone et al. (39) reported that DNA-PKcs inhib-
ited WRN exonuclease and helicase activity, and the additional
presence of Ku alleviated this inhibition. The apparent discrep-
ancy of those data with ours may be caused by the DNA
substrates or purity of the proteins used in the two studies. Our
results would suggest that contamination of the WRN or DNA-
PKcs protein preparation with Ku results in the inhibition of
WRN exonuclease activity mediated by DNA-PK phosphoryla-
tion of WRN. The concentration of DNA-PKcs used in the study
by Yannone et al. (39) was 5–10-fold greater than that of WRN,
raising the possibility that the inhibitory effect was nonspe-
cific. We have shown that Ku-stimulated WRN exonuclease
activity is inhibited markedly by the presence of DNA-PKcs
and that the mutant Ku heterodimer (C-terminal 162-amino
acid deletion of Ku80 subunit with full-length Ku70) that does
not activate DNA-PK is also unable to inhibit WRN exonucle-
ase activity in presence of DNA-PKcs (Fig. 2B). This particular
Ku mutant retains its ability to stimulate WRN exonuclease
activity (Fig. 2). Moreover, addition of kinase inhibitor to the
WRN/Ku/DNA-PKcs reaction restored normal WRN exonucle-
ase activity to the DNA substrate in the presence of Ku. This
result suggests that catalytically active DNA-PK is required for
inhibition of WRN exonuclease activity.
We show that WRN is phosphorylated in vivo after treat-
ment of cells in culture with DNA-damaging agents. We have
used two DNA-damaging agents, 4NQO and bleomycin. 4NQO
is a carcinogen that introduces adducts, which are removed
FIG. 9. A, the presence of kinase inhibitors or PP1 treatment does not
dissociate WRN from DNA-PK. 5 nM DNA-PKcs, 5 nM WRN, and 5 nM
Ku were incubated with wortmannin or PP1 at room temperature for 10
min with exonuclease substrate and buffer. The DNA-protein mixture
was separated by a 4% nondenaturing polyacrylamide gel at 4 °C and
visualized by phosphorimaging. 50, 100, and 200 nM wortmannin (lanes
3, 4, and 5, respectively) or at 0.1, 0.5, and 1 unit of PP1 (lanes 6, 7, and
8, respectively) could not change the supershift over the free substrate
by the WRNKuDNA-PKcs complex. Lane 9 represents same amount of
WRN, Ku, and DNA-PKcs as in lane 8, except 1% SDS was added after
the reaction. B, PP1 treatment does not change the physical association
of WRNKuDNA-PKcs. The in vitro formed complex WRNKuDNA-
PKcs (5 nM each) was treated with either PP1 storage buffer or 0.5 unit
of PP1. The resulting products were immunoprecipitated with antibody
against WRN and followed by immunoblot (IB) with antibody against
WRN, Ku, or DNA-PKcs. Lane 1, WRN  Ku  DNA-PKcs (immuno-
precipitated with WRN antibody). Lane 2, WRN  Ku  DNA-PKcs 
PP1 (immunoprecipitated with WRN antibody). Lane 3, WRN  Ku 
DNA-PKcs (no antibody).
FIG. 10. WRN is phosphorylated in vivo after DNA damage.
HeLa cells were incubated either with 1 or 5 g/ml bleomycin (A) or 0.1
or 0.5 g/ml 4NQO (B) for 5 h in the presence of 10 Ci/ml 32Pi. The cells
were then lysed and immunoprecipitated with antibody against WRN.
Immunoprecipitated proteins were then resolved in a 8–16% acrylam-
ide Tris-glycine gel. The gel was washed and visualized by phosphorim-
aging. Treatment of Hela cells with 25 M wortmannin inhibits WRN
phosphorylation after bleomycin treatment (C). The upper panels show
the silver staining of the same gel to confirm that equal amounts of
proteins were loaded. DNA-PKcs (/) M059K, and DNA-PKcs (	/	)
M059J ganglioblastoma (D) cells were treated with 5 g/ml bleomycin
for 5 h in the presence of 32P. The cells were lysed and immunoprecipi-
tated with an antibody against WRN. The immunoprecipitated proteins
were separated in a 8–16% acrylamide Tris-glycine gel and visualized
by phosphorimaging. The upper panels show the silver staining of the
gel confirming that equal amounts of protein were loaded.
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primarily by nucleotide excision repair, and WS cells are hy-
persensitive to this agent (9). Bleomycin is an x-ray mimetic
agent, and some sensitivity to it has been reported for WS cells
(38). Bleomycin is known to cause various DNA modifications
including DNA adducts, single strand breaks, and DNA dsb
(40). We find that bleomycin induces more WRN phosphoryla-
tion in vivo than does 4NQO (Fig. 10). This supports our hy-
pothesis that WRN plays a role in dsb repair. In vivo phospho-
rylation of WRN was ablated by the DNA-PK inhibitor
wortmannin or in the cell line M059J, which lacks normal
DNA-PKcs function. Because the M059J cells are also very low
in ATM activity (41) we have used A-T cells (an ATM mutated
cell line) to examine if ATM is responsible for the inhibition of
WRN phosphorylation in the M059J cells. We find that the
level of WRN phosphorylation appeared to be similar between
the A-T cells and wild type fibroblast cells (data not shown).
Yannone et al. (39) reported that WRN is phosphorylated by
DNA-PK in undamaged Jurkat cells and human skin fibro-
blasts. As mentioned, we were not able to detect significant
phosphorylation without exposing the cells to stress. This dis-
crepancy may be caused by differences in cell type or procedure.
In addition to its role in recombination and DNA dsb repair,
DNA-PK has also been implicated in several nuclear processes
including transcription and DNA replication. Mutant Chinese
hamster ovary cells lacking the Ku80 subunit or DNA-PKcs
showed a reduced rate of transcription (42). Interaction of Ku
with proteins involved directly in transcription initiation has
also been observed (43, 44). Recently, it has been shown that
Gcn5, a putative transcriptional adapter in human and yeast,
is phosphorylated both in vitro and in vivo by DNA-PK and that
this phosphorylation down-regulates the histone acetyltrans-
ferase activity of Gcn5 (45). We have shown previously that
human WRN is directly associated with RNA polymerase II-
mediated transcription and that WS cells have reduced tran-
scription rates (46). Modulation of WRN function by phospho-
rylation could be part of the transcription process.
DNA-PKcs phosphorylates various proteins in vitro. These
include p53, the large subunit C-terminal domain of RNA po-
lymerase II, and replication protein A (20, 47). Phosphorylation
by DNA-PK of the above proteins has only been shown in vitro,
and we now demonstrate that WRN is a target for this phos-
phorylation in vivo. Physical and functional interactions be-
tween WRN and replication protein A (32) and WRN and p53
(48) have been demonstrated. It is possible that phosphoryla-
tion by DNA-PK regulates WRN and proteins that are associ-
ated with it. Further studies are required to investigate this,
especially under conditions when cells have been exposed to
DNA damage.
It is not uncommon that protein catalytic activities are reg-
ulated by phosphorylation. For example, the replication initia-
tion protein MCM is phosphorylated by cdk2/cyclinA, which in
turns inactivates its helicase activity (49). The intrinsic heli-
case function of NS1, the major nonstructural protein of the
parvovirus minute virus in mice, is dependent on its phospho-
rylation (50). Phosphorylation of SV40 T antigen promotes
double hexamer formation, a process to unwind the SV40 origin
of replication (51). It appears that there is no uniform mode of
regulation by phosphorylation, and some protein functions may
be stimulated, whereas others decrease with phosphorylation.
This regulation may depend upon the specific phosphorylation
sites that are involved locally in different protein interactions,
and there are three phosphorylation sites in WRN. We found
the greatest increase in WRN helicase activity by dephospho-
rylation on the forked duplex substrate, a preferred substrate
for WRN (52). Our finding that the phosphorylation state of
WRN protein affects its helicase activity on that substrate
suggests that WRN engages this structure during specific
events such as replication fork block. Fine tuned regulation of
DNA unwinding at the fork by WRN phosphorylation is an
attractive hypothesis, but further studies are required to ad-
dress the functional importance of phosphorylation on WRN
helicase activity in vivo.
Our finding that the level of phosphorylation of WRN greatly
affects its catalytic activities has important implications for
studies using this purified protein and perhaps for other heli-
case or exonuclease studies. It is possible that differences in
observations regarding characteristics of the unwinding of dif-
ferent substrates by WRN could be explained by differences in
the level of phosphorylation of the recombinant protein(s). This
aspect should be considered in the biochemical studies of WRN
and related proteins.
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